## Review setup

- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full methods, figures, tables, or supplementary data
- **Shared manuscript claim summary** The authors report two FOXG1 missense variants (F215L novel, G252D de novo) identified by direct sequencing in two patients. Using a computational pipeline (in silico prediction, molecular dynamics simulation, molecular docking), they claim both variants are highly deleterious, destabilize the FoxG1 protein, and differentially disrupt function: F215L disrupts the Bmi-1 binding site, while G252D abolishes DNA binding.
- **Visible evidence base** Abstract text only; no methodological details, numerical results, structural figures, or validation metrics provided
- **Missing materials affecting confidence** Full manuscript, methods section, all figures and tables, sequence chromatograms, pathogenicity prediction scores, simulation parameters, docking scores, and any experimental validation

## Reviewer

- **Overall assessment** The abstract presents a clinically motivated computational study of two FOXG1 missense variants. The clinical identification of a novel variant and a de novo known variant is potentially valuable. However, the abstract provides insufficient methodological detail and quantitative evidence to assess the robustness of the computational claims. The conclusions about differential functional impacts (Bmi-1 disruption versus DNA binding loss) are plausible but not verifiable from the supplied material. The study's contribution is incremental, as it applies established computational methods without presenting novel methodology or experimental validation.
- **Who would be interested in the results, and why** Clinicians and geneticists working on FOXG1-related disorders, particularly Rett syndrome variants, would be interested in the variant characterization. Computational biologists studying missense mutation effects on transcription factor structure and function may also find the pipeline relevant. However, the lack of experimental validation limits broader interest.
- **Major strengths** The study addresses a clinically relevant question with potential diagnostic implications. The combination of multiple computational approaches is appropriate for hypothesis generation. The identification of a novel variant adds to the mutational spectrum of FOXG1.
- **Major Concerns** 
  - R1-M1: The abstract claims both variants are "highly deleterious" and cause "protein structure destabilization" without providing any quantitative metrics (e.g., prediction scores, free energy changes, RMSD values). The evidence base is entirely descriptive.
  - R1-M2: The differential functional claims (F215L disrupts Bmi-1 binding, G252D abolishes DNA binding) are presented as definitive conclusions, but no docking scores, binding affinities, or simulation data are shown. The abstract does not indicate whether these differences are statistically or energetically significant.
  - R1-M3: The abstract does not describe the validation of the computational pipeline. Without benchmarking against known benign or pathogenic variants, the reliability of the predictions is unestablished.
- **Minor Comments** 
  - R1-m1: The abstract states "direct sequencing" but does not specify the sequencing method (Sanger versus next-generation) or coverage depth. This information is relevant for assessing variant calling confidence.
  - R1-m2: The phrase "genotype-phenotype correlation" in the final sentence is not supported by any phenotypic data presented in the abstract. Clinical details of patients P1 and P2 are absent.
  - R1-m3: The abstract does not state whether the computational predictions were compared with any existing functional data on FOXG1 variants, which would strengthen the interpretation.
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** 
  - Originality: Low to moderate. The application of established computational methods to two variants is not methodologically novel.
  - Scientific importance: Moderate. The clinical relevance is clear, but the computational-only approach limits the strength of conclusions.
  - Interdisciplinary readership: Limited. The abstract is accessible to computational biologists and clinical geneticists but may not attract a broader audience.
  - Technical soundness: Not assessable from the abstract. No quantitative data or methodological details are provided.
  - Readability for nonspecialists: The abstract is generally clear but uses technical terms (e.g., "molecular dynamic simulation") without brief explanation, which may hinder nonspecialist comprehension.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents plausible hypotheses but lacks the quantitative and methodological detail required to support the strong claims made. A full manuscript with detailed methods, results, and validation would be needed to assess the case.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** "F215L and G252D variants found in the DNA binding domain are highly deleterious mutations that may cause the protein structure destabilization"
- **Evidence pointer** Abstract, location not provided
- **Concern** The claim of high deleteriousness and structural destabilization is made without presenting any quantitative results from the in silico prediction tools or molecular dynamics simulations. No scores, thresholds, or comparative values are given.
- **Why it matters** Without quantitative evidence, the reader cannot evaluate whether the predictions are robust or whether the variants are indeed more destabilizing than typical missense changes. The claim is therefore unsupported as presented.
- **Resolution test** Provide specific prediction scores (e.g., PolyPhen-2, SIFT, CADD) with thresholds, and molecular dynamics metrics (e.g., RMSD, RMSF, free energy of folding changes) with appropriate statistical comparisons.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim support
- **Claim pointer** "F215L mutant is likely to have a great impact on destabilizing the protein structure and the disruption of the Bmi-1 binding site quite significantly. Regarding G252D mutation, it seems to abolish the ability of FoxG1 to bind DNA target"
- **Evidence pointer** Abstract, location not provided
- **Concern** The differential functional impacts are stated with high confidence, but no docking scores, binding free energies, or interaction analyses are provided. The abstract does not indicate whether these differences are statistically significant or within the error of the computational methods.
- **Why it matters** The central conclusion of the study rests on these differential effects. Without quantitative binding data, the claims are speculative and cannot be distinguished from random variation in docking outcomes.
- **Resolution test** Present docking scores (e.g., binding energy in kcal/mol), interaction residue analysis, and a comparison with the wild-type protein. Include error estimates or replicate runs to demonstrate robustness.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Validation
- **Claim pointer** "a computational pipeline by the application of in silico prediction methods, molecular dynamic simulation, and molecular docking approaches was used"
- **Evidence pointer** Abstract, location not provided
- **Concern** The abstract does not describe any validation of the computational pipeline, such as benchmarking against known benign or pathogenic FOXG1 variants or experimental data. Without this, the predictive reliability is unknown.
- **Why it matters** Computational predictions are only as credible as their validation. The absence of any benchmark or experimental comparison means the conclusions are not established.
- **Resolution test** Include a validation section showing the pipeline's performance on a set of known variants (e.g., sensitivity, specificity, or correlation with experimental data).

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Methodological clarity
- **Affected element** Variant identification
- **Evidence pointer** Abstract, location not provided
- **Issue** The abstract states "direct sequencing" without specifying the method or quality metrics.
- **Required correction** Specify the sequencing platform, coverage, and variant calling criteria to support the confidence in variant identification.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Claim scope
- **Affected element** Genotype-phenotype correlation
- **Evidence pointer** Abstract, location not provided
- **Issue** The final sentence claims relevance to "genotype-phenotype correlation," but no phenotypic data for patients P1 and P2 are presented.
- **Required correction** Either provide clinical phenotype summaries or remove the genotype-phenotype claim from the abstract.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Contextualization
- **Affected element** Interpretation
- **Evidence pointer** Abstract, location not provided
- **Issue** The abstract does not compare the computational predictions with any existing functional data on FOXG1 variants.
- **Required correction** Add a brief comparison with known functional effects of other FOXG1 mutations to contextualize the findings.

## Risk / unsupported claims

- The claim that both variants are "highly deleterious" is unsupported without quantitative prediction scores.
- The claim that F215L "disrupts the Bmi-1 binding site quite significantly" is unsupported without docking or interaction data.
- The claim that G252D "abolishes the ability of FoxG1 to bind DNA" is unsupported without binding affinity measurements.
- The claim of relevance to "genotype-phenotype correlation" is unsupported without clinical phenotype data.
- The overall utility of the computational pipeline is not assessable without validation details.